NEW YORK (GenomeWeb) – WaveSense announced today that has signed a strategic marketing agreement with diagnostics distributor Pisces Scientific for its recently CE-IVD marked rare cell enrichment platform and bead-based isolation technology.
Under the terms of the deal, Pisces will market and sell WaveSense products — including the company's EpiSep direct-to-slide enrichment platform and its proprietary paramagnetic bead technology for the selective isolation of cells that express CD138 — to hematology-oncology cytogenetics labs in Ireland and the UK.
According to WaveSense, the EpiSep platform can isolate target cells, such as circulating tumor cells, using only a small specimen and without the need for expensive equipment. Once cells are isolated, a lab can then funnel them for downstream molecular screening including IHC, FISH, PCR, gene expression analyses, or next-generation sequencing.
WaveSense CEO William Curtis has previously said that the company's commercialization plans in Europe are focused on promoting its bead method for isolation of CD138-positive cells from bone marrow.